Investor Relations
About InMed Pharmaceuticals:
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.
Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs.
Robust R&D pipeline of small molecule therapeutics
-
- Three programs in Alzheimer’s disease, AMD and epidermolysis bullosa
- Completed Phase 2 epidermolysis bullosa program, currently seeking partnerships
- Library of proprietary analogs targeting diverse pharmaceutical applications
Alzheimer’s drug candidate demonstrating a multi-factorial approach
-
- Preclinical studies demonstrate neuroprotective effects, reduction in neuroinflammation and an ability to extend the length of neurites
- Oral administration confirmed
Revenue-generating subsidiary
-
- Diverse product portfolio of bioidentical non-intoxicating rare cannabinoids
- Selling cannabinoids to the H&W industry
Strong patent position
- 13 patent families
- Broad range of IP across molecules, manufacturing, formulations and methods of use
Experienced team with a successful track record
- Extensive experience from drug discovery to commercialization
- Pharmaceutical R&D and manufacturing